At the second step of the approach, a PASS Targets software [38] was used to predict 162 interactions of individual drugs that were from obtained datasets with 1553 human protein 163 targets. The sums and absolute values of the differences in the probability estimates of 164 interaction with targets were used as descriptors for drug pairs. The classification models were 165 built using Random Forest along with a method that allows for the applicability domain to be 166 determined. The accuracy of prediction is estimated using a 5-fold cross-validation procedure 167 (see Materials and Methods). To demonstrate the practical benefit of the obtained models, hypertension and cardiac failure (see Table S1 ). Each positive drug pair represents an example of 176 a synergistic or additive DDI that causes a corresponding ADE. The datasets contain, on average, 177 more than 3100 drug pairs belonging to 335 individual drugs and 166 ATC terms of the fourth 178 level ( Table 1) . We performed the following analysis to estimate whether the obtained datasets contain 182 information reflecting DDI-induced ADEs or datasets containing information that is similar to 183 random. One may suggest that the obtained datasets contain more positive drug pairs where both The statistical significance of enrichment was estimated using the chi-squared test. Enrichments 204 for all five ADEs were statistically significant with the highest p-value 0.000035 for ST dataset.
205
As a result, the created datasets are relevant, representative and can be used for further 206 analysis. 208 We used Random Forest to create classification models and the local (Tree) approach to 95.7% of the drug pairs were in the applicability domain of the models (Table 2) . To estimate the relevance of the predicted ADEs, we performed an analysis of the 251 distribution of both-, one-and none-ADE-causing drug pairs among combinations that were 252 predicted to be positives and negatives in relation to the corresponding ADEs (Fig 4) . The observed distribution is similar to that shown in Fig 2. We found that drug pairs that and are in the applicability domain of classification models (Table 4) . (Table 4 ).
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Prediction of DDI-induced cardiovascular ADEs based on drug-target interactions
274
The results of these analyses and the results of 5-fold cross- 
Assessment of the potential mechanisms of DDI-induced ADEs
285
Since DDI-induced ADEs are effectively estimated by using data on predicted DTIs, the 286 corresponding information on drug targets may also be used to reveal the potential mechanisms 287 of cardiovascular ADEs and to influence DDIs in their manifestation. 288 We performed a corresponding analysis for the top 5 none-VT-causing drug pairs from the 289 large dataset with the highest probability scores for ventricular tachycardia (VT) ( Table 5 ). The 290 drugs from these pairs cannot cause ventricular tachycardia when administered separately; 291 however, the drugs possibly cause VT when they are administered together. data on the five ADEs of these individual drugs are represented in Table S3 . 340 We selected drug pairs that were formed by these drugs with at least 100 SRs wherein both 341 drugs are mentioned. For each pair of drugs and each PT from and negative examples of DDI-induced ADEs (see Table 1 ).
348
Step 1 and indications of a drug were measured by a phi correlation coefficient.
371
The final values of the PSs were calculated by using the following logistic regression: 
